Novartis to decide on spinning off $25B generics arm Sandoz by year's end
Rumors of Novartis spinning off its generic and biosimilars arm Sandoz have been circulating since at least 2019.
Now, Sandoz says a decision from Novartis is coming by the end of 2022, with a Sandoz spokesperson adding to Endpoints News, “all options remain open.”
Those options may include a spinoff of the $25 billion subsidiary, which Bloomberg reports sources are favoring internally, or selling it off. Blackstone and the Carlyle Group previously considered a joint offer for Sandoz that could value that unit at up to $25 billion. And prior to that potential offer, EQT and the billionaire Strüngmann brothers were reportedly in talks for a $21 billion bid for Sandoz.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,200+ biopharma pros reading Endpoints daily — and it's free.